Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis

References

• National Asthma Education and Prevention Program. Expert panel report: Guidelines for the diagnosis and management of asthma. NIH publication No. 02–5074, June 2003
   Google Scholar
• Global Initiative for Asthma. Global strategy for asthma management and prevention. NIH Publication No 02–3659 (updated 2005). 2005. National Institutes of Health/National Heart, Lung, and Blood Institute
   Google Scholar
• Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004;170:836–44
   PubMed Web of Science ®Google Scholar
• Dolan CM, Fraher KE, Bleecker ER, et al. Design and baseline characteristics of the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study: a large cohort of patients with severe or difficult-to-treat asthma. Ann Allergy Asthma Immunol 2004;92:32–9
   PubMed Web of Science ®Google Scholar
• Brown ES, Suppes T, Khan DA, et al. Mood changes during prednisone bursts in outpatients with asthma. J Clin Psychopharmacol 2002;22:55–61
   PubMed Web of Science ®Google Scholar
• Huerta C, Lanes SF, Garcia Rodriguez LA. Respiratory medications and the risk of cardiac arrhythmias. Epidemiology 2005;16:360–6
   Google Scholar
• McKee MD, Waddell JP, Kudo PA, et al. Osteonecrosis of the femoral head in men following short course corticosteroid therapy: a report of 15 cases. Can Med Assoc J 2001;164:205–6
   PubMed Web of Science ®Google Scholar
• Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional study. Bone 2006;39:253–9
   PubMed Web of Science ®Google Scholar
• Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764–70
   Google Scholar
• Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003;112:252–62
   PubMed Web of Science ®Google Scholar
• Prussin C, Metcalfe DD. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 2003;111:S486–94
   PubMed Web of Science ®Google Scholar
• Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005;115:459–65
   PubMed Web of Science ®Google Scholar
• Holgate S, Djukanovic R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005;35:408–16
   PubMed Web of Science ®Google Scholar
• Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005;60:309–16
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 2004;59:701–8
   PubMed Web of Science ®Google Scholar
• Vignola AM, Humbert M, Bousquet J, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR. Allergy 2004;59:709–17
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE re combinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184–90
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003;91:154–9
   PubMed Web of Science ®Google Scholar
• Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254–61
   Google Scholar
• Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J 2002;20:73–8
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632–8
   Google Scholar
• Genentech ALTO study; http://clinicalstudyresults.gene.com/q2143g.pdf
   Google Scholar
• Bousquet J, Cabrera P, Berkman N, et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy 2005;60:302–8
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 2002;20:1088–94
   Google Scholar
• Buhl R. Omalizumab (Xolair®) improves quality of life in adult patients with allergic asthma: a review. Respir Med 2002;97:123–9
   Web of Science ®Google Scholar
• Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health-related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax 1992;47:76–83
   PubMed Web of Science ®Google Scholar
• Kianifard F, Gallo PP. Poisson regression analysis in clinical research. J Biopharm Statist 1995;5:115–29
   PubMedGoogle Scholar
• Stokes ME, Davis CS, Koch GG. Categorical Data Analysis using the SAS System, 2nd edn. Cary, North Carolina: SAS Institute Inc., 2000
   Google Scholar